Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01719250 · ClinicalTrials.gov registry record · Early Phase 1
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT01719250: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT01719250 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01719250, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Buparlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Buparlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-12 |
| Est. Completion | 2017-03-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01719250
The ClinicalTrials.gov registry entry for NCT01719250 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01719250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01719250 about?
NCT01719250 is a clinical study titled "Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma". This pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Buparlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth...
What is the current status of trial NCT01719250?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2012-12. Estimated completion is 2017-03-22.
What interventions are being tested in trial NCT01719250?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Buparlisib (DRUG).
Who is sponsoring clinical trial NCT01719250?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.